Affinity Asset Advisors LLC Makes New $3.29 Million Investment in Precision BioSciences, Inc. $DTIL

Affinity Asset Advisors LLC purchased a new position in shares of Precision BioSciences, Inc. (NASDAQ:DTIL) during the first quarter, HoldingsChannel reports. The fund purchased 597,946 shares of the company’s stock, valued at approximately $3,289,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Geode Capital Management LLC increased its stake in Precision BioSciences by 5.5% during the 2nd quarter. Geode Capital Management LLC now owns 77,712 shares of the company’s stock worth $326,000 after purchasing an additional 4,025 shares in the last quarter. Bridgeway Capital Management LLC bought a new position in Precision BioSciences in the second quarter valued at approximately $260,000. Corient Private Wealth LLC bought a new position in Precision BioSciences in the second quarter valued at approximately $425,000. Vanguard Group Inc. boosted its holdings in shares of Precision BioSciences by 21.5% in the third quarter. Vanguard Group Inc. now owns 492,596 shares of the company’s stock valued at $2,719,000 after buying an additional 87,242 shares during the period. Finally, Lynx1 Capital Management LP boosted its holdings in shares of Precision BioSciences by 0.6% in the third quarter. Lynx1 Capital Management LP now owns 1,042,596 shares of the company’s stock valued at $5,755,000 after buying an additional 6,545 shares during the period. Institutional investors and hedge funds own 37.99% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on DTIL shares. HC Wainwright restated a “buy” rating on shares of Precision BioSciences in a report on Thursday, July 9th. Oppenheimer initiated coverage on shares of Precision BioSciences in a research note on Tuesday, June 9th. They issued an “outperform” rating and a $20.00 target price for the company. Weiss Ratings upgraded Precision BioSciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, May 8th. Finally, JonesTrading reissued a “buy” rating and issued a $30.00 price target on shares of Precision BioSciences in a research note on Friday, April 17th. Four research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Precision BioSciences has an average rating of “Moderate Buy” and a consensus target price of $32.25.

Precision BioSciences Price Performance

NASDAQ:DTIL opened at $7.29 on Friday. The stock has a market capitalization of $188.10 million, a PE ratio of -1.99 and a beta of 1.25. Precision BioSciences, Inc. has a 1-year low of $3.53 and a 1-year high of $9.62. The firm has a fifty day simple moving average of $7.35 and a 200 day simple moving average of $6.12. The company has a current ratio of 14.02, a quick ratio of 14.02 and a debt-to-equity ratio of 0.29.

Precision BioSciences (NASDAQ:DTIL) last posted its quarterly earnings results on Tuesday, May 5th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.66) by ($0.09). The firm had revenue of $10.84 million for the quarter, compared to the consensus estimate of $4.05 million. Precision BioSciences had a negative return on equity of 85.37% and a negative net margin of 96.73%. On average, research analysts expect that Precision BioSciences, Inc. will post -2.21 EPS for the current fiscal year.

Precision BioSciences Profile

Precision BioSciences is a clinical‐stage genome editing company that leverages its proprietary ARCUS platform to develop targeted gene therapies. ARCUS, an engineered nuclease derived from a naturally occurring enzyme, enables precise DNA modifications for both in vivo and ex vivo applications. The company’s pipeline spans genetic diseases—including rare monogenic disorders—and immuno‐oncology, where it is advancing allogeneic cell therapy candidates designed to address hematologic malignancies and solid tumors.

Founded in 2006 as a spin‐out from research at the University of North Carolina, Precision BioSciences is headquartered in Durham, North Carolina, with additional research and manufacturing capabilities located in the Research Triangle Park area.